Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.

Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.

AZD0486 seems highly active, including in patients relapsed on Car-T therapy.

Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.